期刊
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
卷 66, 期 11, 页码 2628-2631出版社
OXFORD UNIV PRESS
DOI: 10.1093/jac/dkr317
关键词
dosage; regimen; Clostridium difficile
资金
- Eumedica s.a.
Background: Temocillin, a beta-lactam stable against most beta-lactamases [including extended-spectrum beta-lactamases (ESBLs) and derepressed AmpC cephalosporinases (dAmpC)], has been suggested as an alternative to carbapenems when Pseudomonas can be excluded. Aims: To assess temocillin clinical and microbiological cure rates (CCR and MCR) in infection caused by ESBL/dAmpC-producing Enterobacteriaceae and the effects of different dosage regimens. Methods: Data were collected retrospectively from patients treated for at least 3 days with temocillin for urinary tract infection (n=42), bloodstream infection (n=42) or hospital-acquired pneumonia (n=8) in six centres in the UK. Results: Data on 92 infection episodes were collected. Overall CCR and MCR were 86% and 84% respectively; ESBL/dAmpC status had no effect. Significantly higher CCR and MCR occurred in patients treated with temocillin at optimal dosage [2 g twice daily or renally adjusted equivalent (ORAE)] compared with those treated with a suboptimal dosage (, 2 g twice daily ORAE) (CCR 91% and MCR 92% versus CCR 73% and MCR 63%). This difference was more pronounced in the ESBL/dAmpC-positive subset (CCR 97% and MCR 97% versus CCR 67% and MCR 50%). Conclusions: Clinical and microbiological efficacies of temocillin are unaffected by ESBL/dAmpC production, confirming its potential application as a carbapenem-sparing agent. Both CCR and MCR are optimized by a regimen of 2 g twice daily ORAE in ESBL/dAmpC-positive infection.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据